Renovacor, Inc.
RCORDelisted Dec 1, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799850
Renovacor, Inc. was delisted on Dec 1, 2022; its insiders filed their last Form 4 on Apr 5, 2023; 27 institutions reported holding it in 13F filings for Q3 2022, worth $18.4M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding Renovacor, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 22 | +22 |
| Shares | 0 | 7.19M | +7.19M |
| Value | $0 | $64.5M | +$64.5M |
New holders (22)
Institutions that held Renovacor, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| RTW Investments, LP | 2,187,540 | $19.3M | 0.29% |
| Citadel Advisors LLC | 1,054,433 | $9.54M | 0.01% |
| Sio Capital Management, LLC | 736,323 | $6.66M | 2.15% |
| New Leaf Venture Partners, L.L.C. | 697,436 | $6.31M | 1.82% |
| Cormorant Asset Management, LP | 500,000 | $4.53M | 0.18% |
| Ikarian Capital, LLC | 442,902 | $4.01M | 0.92% |
| Altium Capital Management LP | 388,845 | $3.52M | 0.94% |
| Vanguard Group Inc | 350,632 | $3.17M | 0.00% |
| 683 Capital Management, LLC | 175,000 | $1.58M | 0.08% |
| Pura Vida Investments, LLC | 152,079 | $1.38M | 0.10% |
| HRT Financial LP | 125,696 | $1.14M | 0.01% |
| Affinity Asset Advisors, LLC | 115,000 | $1.04M | 0.41% |
| Kepos Capital LP | 100,000 | $905.0K | 0.06% |
| Morgan Stanley | 51,187 | $463.0K | 0.00% |
| Boothbay Fund Management, LLC | 43,782 | $396.0K | 0.02% |
| D. E. Shaw & Co., Inc. | 25,321 | $229.0K | 0.00% |
| Murchinson Ltd. | 25,000 | $226.0K | 0.11% |
| Susquehanna International Group, LLP | 10,521 | $95.0K | 0.00% |
| Cowen and Company, LLC | 10,000 | $91.0K | 0.00% |
| Bank of America Corp | 745 | $7.00K | 0.00% |
| Royal Bank of Canada | 200 | $2.00K | 0.00% |
| UBS Group AG | 18 | $0 | 0.00% |
Sold out (0)
Institutions that held Renovacor, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.